1. Introduction {#sec1}
===============

Age-related macular degeneration (AMD) is a progressive neurodegenerative disease and the leading cause of irreversible blindness among individuals aged 65 and older, particularly in western countries \[[@B1]\]. With the ageing population, the number of people with AMD is estimated to increase by approximately 50% by the year 2020 and the burden of this disease is set to grow \[[@B2]\]. Macular degenerative lesions are manifested by drusen formation, retinal pigment epithelium (RPE) changes, retinal pigment epithelium and choroid capillary layer, Bruch*ʼ*s membrane lesion, geographic atrophy of the central fovea, exudative AMD with choroidal neovascularization, retinal pigmentary epithelium detachment, or submacular disciform scarring changes. The pathological hallmark of the disease is amorphous deposits of protein and lipid, termed drusen \[[@B3]\]. Drusen---colloid material (lipids, phospholipids, and collagen) excrescences, similar to hyaline---accumulate in the retina, in Bruch\'s membrane underlying the retinal pigment epithelium. This process is associated with retinal pigment epithelium and progressive degeneration of photoreceptors \[[@B4]\]. Drusen disturb oxygenous metabolism and determine the degeneration of photoreceptors, while visual function impairment is associated with the quantity of damaged photoreceptors. In the fovea, where there is the largest quantity of photoreceptors, cones dominate, whereas the parafoveal region, where rods dominate, surrounds the fovea. In the early stages, photoreceptors are mostly damaged in the parafovea.

AMD is a complex disease to which many factors contribute: body ageing together with pathological changes, such as pathogenic oxidative stress, inflammatory processes, changes of the extracellular matrix, biological activity changes in the retinal pigment epithelium, and genetic factors---all of them are important in the pathogenesis of this disease \[[@B5]\]. With advancing age, there is a deposit of lipid particles in a normal Bruch\'s membrane leading to the creation of a lipid wall, external to the RPE basal lamina, impairing nutrient exchange between the choriocapillaris and the RPE and compromising retinal function \[[@B6], [@B7]\]. The observation that the location of the lipid wall is the same as and precedes the basal linear deposits and drusen suggests its contribution to drusen formation \[[@B8]\]. Indeed, lipids (both esterified and unesterified cholesterol and phosphatidylcholine) represent at most less than fifty percent of the volume of drusen \[[@B9]\]. Koskela et al. state that the accumulation of oxidized lipids seems to play a pivotal role in the development of AMD \[[@B10]\]. For instance,*CYP4F2* is involved in the production of 20-hydroxyeicosatetraenoic acid (20-HETE), a molecule that is proinflammatory and can induce hyperlipidemia \[[@B11], [@B12]\].*CYP4F2* is also an important endobiotic metabolizing enzyme involved in the metabolism of fatty acids such as arachidonic acid, medium and very long polyunsaturated fatty acids, eicosanoids such as leukotriene B4 (LTB4), prostaglandins, and lipoxins implicating its importance in maintaining liver polyunsaturated fatty acids (PUFA) levels and inflammatory status \[[@B13]\]. The polymorphism (rs2108622, V433M) in the CYP4F2 gene with a valine to methionine substitution at amino acid 433 was found to be associated with changes in all these processes and, for instance, Fava et al. \[[@B14]\] found that CYP4F2 M433 (V433M) carriers had significantly higher levels of waist, triglycerides, blood pressure (BP), and a composite sum of metabolic syndrome (MetS) phenotypes (MetS score) beside lower high density lipoprotein (HDL) cholesterol with respect to V-homozygotes.

Knowing that the main pathological changes of age-related macular degeneration are drusen, which include about 40% lipids, the attempts to find a relation between age-related macular degeneration and the gene rs2108622 controlling lipid metabolism have been made.

2. Materials and Methods {#sec2}
========================

Permission to undertake the study was obtained from the Ethics Committee for Biomedical Research. The study was conducted in the Lithuanian University of Health Sciences (LUHS), Neuroscience Institute, Ophthalmology laboratory (Number BE-2-/13).

The study included patients (*n* = 190) with early age-related macular degeneration and patients (*n* = 181) with exudative age-related macular degeneration and a random sample of the population *n* = 210 (control group).

2.1. Control Group Formation {#sec2.1}
----------------------------

The control group consisted of subjects who had no ophthalmologic pathology on examination and who agreed to take part in this study. The control group involved 210 subjects, who matched the early AMD and eAMD group structure according to their age and gender. Thus it comprised 161 women and 49 men with their ages ranging from 50 to 90 years.

The control group was created by taking into consideration the distribution of age and gender in the early AMD and eAMD group ([Table 1](#tab1){ref-type="table"}). Therefore, the medians of the patient age of the control group and the early and eAMD group did not differ statistically significantly (NS).

During analysis of data, study subjects were grouped according to their age (younger than 65 years and 65 years and older).

2.2. Ophthalmological Evaluation {#sec2.2}
--------------------------------

All study subjects were evaluated by slit-lamp biomicroscopy to assess corneal and lenticular transparency. Classification and grading of lens opacities were performed according to the Lens Opacities Classification System III. Best corrected visual acuity (BCVA) was measured using the standard procedure adapted for the Age-Related Eye Disease Study (AREDS) at a 5-meter distance from the chart (letters on the ETDRS logMAR chart), for subjects with sufficiently reduced vision, at 1 meter. At each examination, intraocular pressure was measured. Pupils were dilated with tropicamide 1%, after which fundoscopy, using slit-lamp biomicroscopy with a double aspheric lens of +78 diopters, was performed. For detailed analysis of the macula, colour fundus photographs of the macula, centred at 30° to the fovea, were obtained with a Visucam NM Digital camera (Carl Zeiss Meditec AG, Germany).

The classification system of AMD formulated by the Age-Related Eye Disease Study \[[@B15]\] was used: early AMD consisted of a combination of multiple small drusen and several intermediate drusen (63--124 *μ*m in diameter) or retinal pigment epithelial abnormalities; intermediate AMD was characterized by the presence of extensive intermediate drusen and at least one large drusen (≥125 *μ*m in diameter) or geographic atrophy (GA) not involving the centre of the fovea; and advanced AMD was characterized by GA involving the fovea and/or any of the features of neovascular AMD \[[@B16]\]. Early AMD and eAMD were diagnosed by two ophthalmologists. Simultaneous spectral-domain optical coherence tomography (SD OCT; 870 nm, 40 000 A-scans/sec) and/or fluorescein angiography (FA) were performed for all AMD patients. SD OCT was carried out with Nidek RS 3000 advanced. FA, following fundus photography, patients underwent intravenous retinal fluorescein angiography. According to our standard technique, 5 mL of a 20% solution of sodium fluorescein was rapidly injected into the antecubital vein; then all phases of fluorescein transit in the posterior pole of the study eye were photographically recorded. Some late angiograms of the fellow eye were taken to confirm or exclude exudative AMD.

The following subject exclusion criteria were used: (i) unrelated eye disorders, for example, high refractive error, cloudy cornea, lens opacity (nuclear, cortical, or posterior subcapsular cataract) except minor opacities, keratitis, acute or chronic uveitis, glaucoma, or diseases of the optic nerve; (ii) systemic illnesses, for example, diabetes mellitus, malignant tumours, systemic connective tissue disorders, chronic infectious diseases, or conditions following organ or tissue transplantation; (iii) ungraded colour fundus photographs resulting from obscuration of the ocular optic system or because of fundus photograph quality.

2.3. DNA Extraction and Genotyping {#sec2.3}
----------------------------------

The DNA extraction and analysis of the gene polymorphism of*CYP4F2*(rs2108622) were carried out at the Laboratory of Ophthalmology at the Institute of Neuroscience of LUHS. DNA was extracted from 200 *μ*L venous blood (white blood cells) using a DNA purification kit based on the magnetic beads method (MagJET Genomic DNA Kit, Thermo Scientific) or the silica-based membrane technology utilizing a genomic DNA extraction kit (GeneJET Genomic DNA Purification Kit, Thermo Scientific), according to the manufacturer\'s recommendations.

The genotyping of*CYP4F2*(rs2108622) was carried out using the real-time polymerase chain reaction (PCR) method. Single-nucleotide polymorphism was determined using TaqMan® Drug Metabolism assay (Thermo Scientific).

The genotyping was performed using a Rotor-Gene Q real-time PCR quantification system (Qiagen, USA). The real-time PCR reagents (2x TaqMan® Universal Master Mix, TaqMan® Drug Metabolism assay, nuclease-free water) were taken out from an environment of −20°C and were thawed at room temperature. The thawed reagents were centrifuged (10 000 rpm) and stored in an ice tub. Appropriate real-time PCR mixtures of*CYP4F2*(rs2108622) were prepared for determining a single-nucleotide polymorphism.

A PCR reaction mixture (9 *μ*L) was poured into the 72 wells of the Rotor-Disc, and then 1 *μ*L of matrix DNA of the samples (\~10 ng) and 1 *μ*L of negative control (−K) were added.

The Allelic Discrimination program was used during the real-time PCR. Then, the assay was continued following the manual provided by the manufacturer (<http://www.qiagen.com/>, Allelic Discrimination). After that, the Allelic Discrimination program was completed, and the genotyping results were received. The program determined the individual genotypes according to the fluorescence intensity rate of different detectors (VIC and FAM).

2.4. Statistical Analysis {#sec2.4}
-------------------------

Statistical analysis was performed using the SPSS/W 20.0 software (Statistical Package for the Social Sciences for Windows, Inc., Chicago, Illinois, USA). The data are presented as absolute numbers with percentages in brackets, average values, and standard deviations (SD). The frequencies of genotypes (in percentage) are presented in [Table 2](#tab2){ref-type="table"}.

Hardy-Weinberg analysis was performed to compare the observed and expected frequencies of rs2108622 using the *χ* ^2^ test in all groups. The distribution of the rs2108622 single-nucleotide polymorphism (SNP) in the AMD and control groups was compared using the *χ* ^2^ test or the Fisher exact test. Binomial logistic regression analysis was performed to estimate the impact of genotypes on AMD development. Odds ratios and 95% confidence intervals are presented. The selection of the best genetic model was based on the Akaike Information Criterion (AIC); therefore, the best genetic models were those with the lowest AIC values.

Differences were considered statistically significant when *p* \< 0.05.

3. Results {#sec3}
==========

A total of 190 patients with early AMD and 181 patients with eAMD were enrolled into the analysis according to the subject inclusion and exclusion criteria. The control group comprised 210 persons. There were 76.7% (*n* = 161) of women in the control group, 70% (*n* = 133) of women in the early AMD group, and 67.4% (*n* = 122) of women in the eAMD group.

The genotyping of rs2108622 was performed in patients with early AMD and eAMD and in the control group subjects (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}).

The distribution of the analyzed rs2108622 genotype and allele frequencies in early AMD patients, eAMD patients, and controls matched the Hardy-Weinberg equilibrium. rs2108622 gene polymorphism analysis in the overall group did not reveal any differences in the genotypes distribution between patients with AMD and control group subjects.

The comparison of the rs2108622 genotype frequency by age groups did not reveal significant differences as well ([Table 4](#tab4){ref-type="table"}).

The comparison of the rs2108622 genotype in males and females between patients with early AMD and the control group did not show statistically significant differences but revealed statistically significant differences between males and females with eAMD. The*CYP4F2*(1347C\>T)*T/T* genotype was more frequent in males with eAMD (10.2% versus 0.8%; *p* = 0.0052). When comparing the*CYP4F2*genotype distribution in females with eAMD and healthy females significant differences were also revealed. The*CYP4F2*(1347C\>T)*T/T*genotype was less frequently present in eAMD females compared to healthy controls (0.8% versus 6.2%; *p* = 0.027) ([Table 5](#tab5){ref-type="table"}).

Binomial logistic regression analysis in the patients with NeAMD and in the control group was performed ([Table 6](#tab6){ref-type="table"}). Similarly, binomial logistic regression analysis in the patients with eAMD and in the control group was carried out ([Table 7](#tab7){ref-type="table"}). These analyses did not detect any differences in the models between patients with AMD and control group subjects.

Binomial logistic regression analysis in males and females with AMD and in the control group was performed ([Table 8](#tab8){ref-type="table"}). In the female AMD group this analysis revealed that the recessive (*p* value = 0.049) variables were statistically significant ([Table 8](#tab8){ref-type="table"}).

Binomial logistic regression analysis in the males with early AMD and in the control group by age was performed ([Table 9](#tab9){ref-type="table"}). This analysis found that the additive (*p* = 0.041) variables were statistically significant in the group aged over 65 years.

Binomial logistic regression analysis in the males with eAMD and in the control group by age was performed ([Table 10](#tab10){ref-type="table"}). This analysis displayed that the codominant (*p* = 0.026) variables in the group under 65 years old were statistically significant ([Table 10](#tab10){ref-type="table"}). Moreover, the dominant (*p* = 0.037) and additive (*p* = 0.015) variables were statistically significant in the group of over 65 years ([Table 10](#tab10){ref-type="table"}).

4. Discussion {#sec4}
=============

It is known that changes in the metabolism of cholesterol, particularly of HDL, may influence drusen accumulation and consequently promote AMD development \[[@B17]\]. Cholesterol can be obtained from systemic sources or recycled in the retina, through the circulation of blood lipids. Thus, the retinal rod cells are capable of using both lipids from the liver and those recycled from RPE \[[@B18]\]. With advancing age, there is a deposit of lipid particles in a normal BrM leading to the creation of a lipid wall, external to the RPE basal lamina, impairing nutrient exchange between the choriocapillaris and the RPE which compromises retinal function; thus that accumulation of lipids seems to play a pivotal role in the development of AMD \[[@B6], [@B7], [@B10]\]. In addition to genetic predisposition, which accounts for 70% of the risk of the disease development \[[@B19]\], advanced age is also considered a risk factor, which results in the deposition of lipid particles and formation of drusen in the retina, thereby affecting retinal function \[[@B18]\]. The study done by Björkhem et al. states that the most important enzymatic oxidation of cholesterol takes place with the involvement of the*CYP46A1* and*CYP27A1*loci of cytochrome P450 family which forms 24-hydroxycholesterol (24-Hch) and 27-hydroxycholesterol (27-Hch), respectively \[[@B19]\]. High levels of 27-Kch have been reported in macrophages foam cells and in atherosclerotic plaque but have not been documented in the retina \[[@B20], [@B21]\]. These population-based genetic studies coupled with animal experiments indicate the prominent role of cholesterol metabolism in the AMD pathology \[[@B20], [@B21]\]. The rs754203 SNP in the*CYP46A1* gene was evaluated by Fourgeux et al. and no significant difference between the*CYP46A1* genotypes in the AMD and control groups was observed \[[@B22]\]. At the same time, the data from three studies are controversial, due to conflicting results. Therefore, we aimed to determine the frequency of the genotype of 1347C\>T (rs2108622) in*CYP4F2* (which is involved in lipid metabolism) in patients with early and exudative AMD. The data of our analysis of rs2108622 polymorphism did not reveal any differences in the distribution of C/C, C/T, and T/T genotypes between the early AMD group, exudative AMD group, and the control group (51.6%, 42.6%, and 5.8% in early AMD group, 56.35%, 39.78%, and 3.87% in the exudative AMD group, and 53.33%, 39.05%, and 7.62%, in the control group, resp.). The*CYP4F2*(1347C\>T)*T/T* genotype was more frequent in males with exudative AMD (10.2% versus 0.8%; *p* = 0.0052), and the comparison of the*CYP4F2*genotype distribution in females with exudative AMD and healthy females determined significant differences. The*CYP4F2*(1347C\>T)*T/T*genotype was less frequently present in exudative AMD females compared to healthy control females (0.8% versus 6.2%; *p* = 0.027). To interpret our results, the research should be repeated with a larger sample size. However, exposure to environmental hazards has been associated with diseases in humans. The identification of single-nucleotide polymorphism (SNP) in human populations exposed to different environmental hazards is vital for detecting the genetic risks of some important human diseases \[[@B23]\]. Yang et al. study sought to structure a genetic score for smoking behaviour in a Chinese population. They tested GWAS-significant SNPs associated with smoking behaviour in a Chinese population and structured three types of genetic scores. They found that the effects of the three types of genetic score were similar; however, to best extrapolate and understand these types of results, the unweighted genetic score represents the ideal choice. Furthermore, the genetic score was significantly associated with smoking behaviour (smoking status and SI at ≤18 years of age). The results of this study may guide relevant health education for those with a high genetic score and promote smoking control to improve the health of the population \[[@B24]\]. It is possible that the genotype distribution of rs2108622 in the patients with exudative age-related macular degeneration (AMD) and the control subjects by gender can result from gene-environment interactions. One of the environmental risk factors could be smoking.

We found no studies analyzing the*CYP4F2*(1347C\>T, rs2108622) gene polymorphism in patients with age-related macular degeneration; thus we can only compare the genotyping results in our control group with results obtained in other studies.

Results of the control groups with rs2108622 polymorphism distribution in the other studies are shown in [Table 11](#tab11){ref-type="table"}. It shows quite similar results to our study except for one study in Saudi Arabia \[[@B25]\] but it remains unclear if the reason for this is ethnicity, the size of control group, or something else.

There are many studies analyzing genes that take part in lipid metabolism and about systemic lipoproteins, but results are conflicting. Moreover, conflicting results have been reported with regard to the associations of AMD with serum HDL concentration and the genes involved in lipid metabolism. Some authors agree that increased serum cholesterol levels increase AMD development \[[@B16], [@B31]\]; however, other authors disagree \[[@B32]\] and some others reported no significant associations \[[@B33]--[@B36]\]. Ebrahimi and Handa suggested that before excluding the role of systemic lipids in AMD, the role of plasma lipids in the context of genotype could be examined to identify predisposition in a subset of patients at risk of developing AMD due to genotype and plasma lipid levels \[[@B37]\]. As the major SNPs involved in the HDL pathway, CETP rs3764261, LPL rs12678919, and LIPC rs10468017 have been shown to be associated with AMD in a genome-wide association studies (GWAS) \[[@B38]\]. However, previous studies on the reported HDL cholesterol metabolism genes showed contradictory results, especially in several GWAS; moreover, their genetic susceptibility to AMD varied in diverse populations \[[@B39]--[@B41]\]. On the other hand, different studies have found an inverse correlation with HDL and AMD risk. Reynolds et al. \[[@B42]\] recently demonstrated that elevated HDL is associated with a reduced risk of advanced AMD, especially the neovascular (NV) subtype (*p* value \< 0.05, 0.03, resp.), and that higher low density lipoprotein (LDL) is associated with an increased risk of advanced AMD and the NV subtype (*p* value \< 0.03, 0.04, resp.). When looking for an association of serum lipids with advanced AMD in multivariate modeling, Reynolds et al. also found significant trends with a higher quartile of LDL and increasing AMD risk (*p* for trend \<0.03, 0.01). Higher total cholesterol was also associated with AMD risk when controlling for all covariates and genotypes \[[@B42]\].

A Klein et al. study \[[@B43]\] examined 6950 participants from the Beaver Dam Eye Study (BDES), Blue Mountains Eye Study (BMES), and Rotterdam Study (RS). There were few associations among total cholesterol, HDL-C, total cholesterol/HDL-C ratio, and non-HDL-C and the incidence of early AMD, soft indistinct (SI) drusen, large area of drusen, pigmentary abnormalities, late AMD, and exudative AMD. Direct associations of HDL-C with the incidence of pure geographic atrophy (GA) were present in the BDES and RS cohorts but not the BMES cohort. The use of statins was not associated with any incidence of an AMD outcome in any of the cohorts. In the BDES,*CETP* rs1864163 and*LPL* rs281 were protective against the development of large drusen area in the macula and*CETP* rs3764261 was protective against the development of pure GA. In the RS,*CETP* rs3764261 was linked to an increased risk of late AMD, pure GA, and exudative AMD.*CETP* rs1864163 was related to a decreased risk of the incidence of early AMD and large drusen area.*ABCA1* rs1883025 was associated with a decreased risk of large SI drusen.*LPL* rs281 was associated with a decreased risk of a large drusen area in the macula. In the BMES, none of these SNPs were found to be significantly associated with any AMD outcomes, although marginally nonsignificant associations were found between*ABCA1* rs1883025/T and pure GA and between*LIPC* rs7163555 and exudative AMD. Mean HDL-C increased in each of the three cohorts with each additional risk allele for*CETP* rs376426 and decreased with each additional risk allele for*CETP* rs1864163 and*ABCA1* rs1883025 (all *p* \< 0.05). There were no consistent statistically significant associations between*LIPC* or*LPL* and HDL-C or between any of the lipid genes and total cholesterol \[[@B43]\]. In a meta-analysis, after correction for multiple testing, they did not find an association between serum lipids or lipid pathway genes and the incidence or progression of AMD over a 20-year period using data from three population-based cohort studies, the BDES, BMES, and RS \[[@B43]\].

In addition to being one of the major AMD-susceptibility genes, perhaps accounting for approximately 30%--50% of AMD patients, CFH might interact with lipid metabolism to affect the disease risk \[[@B44]\]. Such interactions among genes in the complement system and HDL metabolism pathway might be proposed as one potential explanation for the lack of heritability \[[@B45]\]. However, whether the interaction is present or not and whether or not these interactions occur with different genes in the HDL metabolism pathway remain unclear \[[@B45]\].

In conclusion, our results suggest that the CYP4F2 (rs2108622) gene polymorphism had no predominant effect on the development of early and eAMD when compared to the control group. But the*CYP4F2*(1347C\>T)*T/T* genotype was more frequent in males with eAMD compared to females (10.2% versus 0.8%; *p* = 0.0052), and the comparison of the*CYP4F2*genotype distribution in females with eAMD and healthy females did not reveal significant difference. The*CYP4F2*(1347C\>T)*T/T*genotype was less frequently present in eAMD females compared to healthy control females (0.8% versus 6.2%; *p* = 0.027), but this must be replicated with a larger sample size to prove these results, as we know that T/T genotype is wild and very rare.
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###### 

Demographic characteristics of the study population.

  Characteristic          Group         *p* value                   
  ----------------------- ------------- ------------- ------------- ----
  Men, *n* (%)            57 (30.0)     59 (32.6)     49 (23.3)     NS
  Women, *n* (%)          133 (70.0)    122 (67.4)    161 (76.7)    NS
  Age median (min; max)   66 (50; 93)   76 (50; 90)   52 (20; 90)   NS

NS: nonsignificant.

###### 

Frequency of the CYP4F2 rs2108622 genotypes in the patients with early AMD and in the control group.

  ------------------------------------------------------------------------------------
  Genotype/allele   Frequency (%)                                 
  ----------------- --------------- ------- ------------- ------- --------------------
  Genotype                          0.854                 0.277    

   T/T              16 (7.62)               11 (5.8)              *χ* ^2^ = 0.8676 \
                                                                  *p* = 0.6481

   T/C              82 (39.05)              81 (42.6)             

   C/C              112 (53.33)             98 (51.6)             

    *Total*         *210 (100)*             *190 (100)*           

  Allele                                                          

   T                114 (25.33)             103 (31.21)           

   C                336 (74.67)             277 (68.79)           
  ------------------------------------------------------------------------------------

*p* value: significance level (alpha = 0.05); *p* value HWE: significance level (alpha = 0.05) by Hardy-Weinberg equilibrium.

###### 

Frequency of the CYP4F2 rs2108622 genotypes in the patients with eAMD and in the control group.

  -------------------------------------------------------------------------------------
  Genotype/allele   Frequency (%)                                  
  ----------------- ---------------- ------- ------------- ------- --------------------
  Genotype                           0.854                 0.187    

   T/T              16 (7.62)                7 (3.87)              *χ* ^2^ = 2.5012 \
                                                                   *p* = 0.2863

   T/C              82 (39.05)               72 (39.78)            

   C/C              112 (53.33)              102 (56.35)           

    *Total*         *210 T (1000)*           *181 (100)*           

  Allele                                                           

   T                114 (25.33)              86 (23.75)            

   C                336 (74.67)              276 (76.25)           
  -------------------------------------------------------------------------------------

*p* value: significance level (alpha = 0.05); *p* value HWE: significance level (alpha = 0.05) by Hardy-Weinberg equilibrium.

###### 

Frequency of *CYP4F2* rs2108622 genotype in early AMD patients, in eAMD patients and controls by age.

  Genotype                                                                                                                     \<65 years   *p* value     ≥65 years     *p* value              
  ---------------------------------------------------------------------------------------------------------------------------- ------------ ------------- ------------- ------------ --------- -------
   Frequency of *CYP4F2 (1347C\>T; V433M) rs2108622* genotype in the patients with early AMD and the control subjects by age                                                                   
  TT                                                                                                                           4 (4.5)      11 (7.1)      0.538         7 (6.9)      5 (9.3)   0.847
  TC                                                                                                                           39 (43.8)    59 (37.8)     42 (41.6)     23 (42.6)              
  CC                                                                                                                           46 (51.7)    86 (55.1)     52 (51.5)     26 (48.1)              
  Allele                                                                                                                                                                                       
   T                                                                                                                           47 (26.4)    81 (25.96)    56 (27.72)    33 (30.55)             
   C                                                                                                                           131 (73.6)   231 (74.04)   146 (72.28)   75 (69.45)             
                                                                                                                                                                                               
   Frequency of *CYP4F2 (1347C\>T; V433M) rs2108622* genotype in the patients with eAMD and the control subjects by age                                                                        
  TT                                                                                                                           1 (3.8)      11 (7.1)      0.751         6 (3.9)      5 (9.3)   0.266
  TC                                                                                                                           9 (34.6)     59 (37.8)     63 (40.6)     23 (42.6)              
  CC                                                                                                                           16 (61.5)    86 (55.1)     86 (55.5)     26 (48.1)              
  Allele                                                                                                                                                                                       
   T                                                                                                                           11 (21.15)   81 (25.96)    75 (24.19)    33 (30.55)             
   C                                                                                                                           41 (78.85)   231 (74.04)   235 (75.81)   75 (69.45)             

*p* value: significance level (alpha = 0.05); *p* value HWE: significance level (alpha = 0.05) by Hardy-Weinberg equilibrium.

###### 

Frequency of CYP4F2 rs2108622 genotype in the patients with early AMD and eAMD and the control subjects by gender.

  Genotype                                                                                                                                                               Males              *p* value    Females   *p* value                       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ------------ --------- ----------------- ------------- ---------
   Frequency of *CYP4F2 (1347C\>T; V433M) rs2108622* genotype in the patients with early age-related macular degeneration (AMD) and the control subjects by gender                                                                                 
  TT                                                                                                                                                                     6 (10.5)           6 (12.2)     0.149     5 (3.8)           10 (6.2)      0.429
  TC                                                                                                                                                                     27 (47.4)          23 (46.9)    1         54 (40.6)         59 (36.6)     0.547
  CC                                                                                                                                                                     24 (42.1)          20 (40.8)    1         74 (55.6)         92 (57.1)     0.814
  Allele                                                                                                                                                                                                                                            
   T                                                                                                                                                                     39 (34.51)         35 (35.71)             64 (24.06)        79 (24.53)     
   C                                                                                                                                                                     75 (65.49)         63 (64.29)             202 (75.94)       243 (75.47)    
                                                                                                                                                                                                                                                   
   Frequency of *CYP4F2 (1347C\>T; V433M) rs2108622* genotype in the patients with exudative age-related macular degeneration (AMD) and the control subjects by gender                                                                             
  TT                                                                                                                                                                     *6 (10.2)* ^*∗*^   6 (12.2)     0.767     *1 (0.8)* ^*∗*^   *10 (6.2)*    *0.027*
  TC                                                                                                                                                                     22 (37.7)          23 (46.9)    0.333     50 (41.0)         59 (36.6)     0.462
  CC                                                                                                                                                                     31 (52.5)          20 (40.8)    0.250     71 (58.2)         92 (57.1)     0.904
  Allele                                                                                                                                                                                                                                            
   T                                                                                                                                                                     34 (28.81)         35 (35.71)             50 (20.66)        79 (24.53)     
   C                                                                                                                                                                     84 (71.19)         63 (64.29)             192 (79.34)       243 (75.47)    

^*∗*^ *p* = 0.0052.

*p* value: significance level (alpha = 0.05); *p* value HWE: significance level (alpha = 0.05) by Hardy-Weinberg equilibrium.

###### 

Binomial logistic regression analysis of the *CYP4F2 (1347C\>T; V433M) rs2108622* in the patients with early AMD and in the control group.

  Model          Genotype               OR (95% CI)            *p* value   AIC
  -------------- ---------------------- ---------------------- ----------- ---------
  Codominant     T/T                    0.786 (0.348; 1.774)   0.562       558.646
  T/C            1.129 (0.750; 1.700)   0.562                              
  Dominant       T/C + T/T              1.073 (0.724; 1.589)   0.726       557.394
  Recessive      T/T                    0.745 (0.337; 1.649)   0.468       556.983
  Overdominant   T/C                    1.160 (0.778; 1.729)   0.466       556.987
  Additive       ---                    1.002 (0.730; 1.376)   0.990       557.517

###### 

Binomial logistic regression analysis of the *CYP4F2 (1347C\>T; V433M) rs2108622* in the patients with eAMD and in the control group.

  Model          Genotype               OR (95% CI)            *p* value   AIC
  -------------- ---------------------- ---------------------- ----------- ---------
  Codominant     T/T                    0.480 (0.190; 1.215)   0.121       543.306
  T/C            0.964 (0.637; 1.460)   0.863                              
  Dominant       T/C + T/T              0.885 (0.593; 1.320)   0.550       543.530
  Recessive      T/T                    0.488 (0.196; 1.214)   0.123       541.336
  Overdominant   T/C                    1.031 (0.687; 1.549)   0.883       543.866
  Additive       ---                    1.204 (0.865; 1.675)   0.271       542.671

###### 

Binomial logistic regression analysis of the *CYP4F2 (1347C\>T; V433M) rs2108622* in males and females with eAMD and in the control group.

  Model           Genotype               OR (95% CI)              *p* value   AIC
  --------------- ---------------------- ------------------------ ----------- -----------
  Female                                                                       
   Codominant     T/T                    0.130 (0.016; 1.036)     0.054       386.317
  T/C             1.098 (0.674; 1.788)   0.707                                
   Dominant       T/C + T/T              0.958 (0.595; 1.542)     0.859       390.898
    *Recessive*   *T/T*                  *0.125 (0.016; 0.988)*   *0.049*     *384.458*
   Overdominant   T/C                    1.201 (0.741; 1.945)     0.458       390.379
   Additive       ---                    1.220 (0.805; 1.850)     0.348       390.041
  Male                                                                         
   Codominant     T/T                    0.645 (0.182; 2.282)     0.497       153.306
  T/C             0.617 (0.274; 1.389)   0.243                                
   Dominant       T/C + T/T              0.623 (0.290; 1.339)     0.225       151.311
   Recessive      T/T                    0.811 (0.244; 2.696)     0.733       152.676
   Overdominant   T/C                    0.672 (0.311; 1.452)     0.312       151.767
   Additive       ---                    1.357 (0.770; 2.392)     0.291       151.666

###### 

Binomial logistic regression analysis of the *CYP4F2 (1347C\>T; V433M) rs2108622* in the males with early AMD and in the control group by age.

  Model           Genotype               OR (95% CI)             *p* value   AIC
  --------------- ---------------------- ----------------------- ----------- --------
  \<65                                                                        
   Codominant     T/T                    1.727 (0.296; 10.082)   0.544       97.984
  T/C             1.524 (0.551; 4.212)   0.417                               
   Dominant       T/C + T/T              1.555 (0.584; 4.135)    0.377       96.003
   Recessive      T/T                    1.385 (0.259; 7.414)    0.704       96.648
   Overdominant   T/C                    1.387 (0.528; 3.639)    0.507       96.350
   Additive       ---                    0.717 (0.335; 1.533)    0.391       96.050
  ≥65                                                                         
   Codominant     T/T                    0.077 (0.006; 1.023)    0.052       44.437
  T/C             0.154 (0.016; 1.471)   0.104                               
   Dominant       T/C + T/T              0.128 (0.014; 1.152)    0.067       42.960
   Recessive      T/T                    0.280 (0.046; 1.705)    0.167       45.938
   Overdominant   T/C                    0.500 (0.115; 2.175)    0.355       46.931
    *Additive*    ---                    3.422 (1.052; 11.130)   *0.041*     42.961

###### 

Binomial logistic regression analysis of the *CYP4F2 (1347C\>T; V433M) rs2108622* in the males with eAMD and in the control group by age.

  Model           Genotype               OR (95% CI)             *p* value   AIC
  --------------- ---------------------- ----------------------- ----------- --------
  \<65                                                                        
   Codominant     T/T                    1.583 (0.129; 19.422)   0.719       44.539
  T/C             0.559 (0.091; 3.446)   0.531                               
   Dominant       T/C + T/T              0.713 (0.141; 3.612)    0.682       43.065
   Recessive      T/T                    2.00 (0.177; 22.550)    0.575       42.948
   Overdominant   T/C                    0.518 (0.089; 3.002)    0.463       42.662
   Additive       ---                    1.045 (0.298; 3.667)    0.945       43.230
  ≥65                                                                         
   Codominant     T/T                    0.062 (0.005; 0.720)    *0.026*     53.304
  T/C             0.123 (0.014; 1.108)   0.062                               
    *Dominant*    T/C + T/T              0.103 (0.012; 0.871)    *0.037*     51.927
   Recessive      T/T                    0.248 (0.048; 1.276)    0.095       56.239
   Overdominant   T/C                    0.417 (0.105; 1.661)    0.215       57.207
    *Additive*    ---                    3.670 (1.282; 10.502)   *0.015*     52.149

###### 

Frequency of CYP4F2 rs2108622 genotypes in the control groups from other studies.

  --------------------------------------------------------------------------------
      Study                             Country     VV%     VM%     MM%    Total
  --- --------------------------------- ----------- ------- ------- ------ -------
  1   Our study                         Lithuania   53.33   39.05   7.62    

  2   Ivashchenko et al.\               Russia      57.1    34.1    7.7    ---
      2013 \[[@B26]\]                                                      

  3   Cen et al. 2010 \[[@B27]\]        China       52.0    41.0    7.0    ---

  4   Teichert et al. 2009 \[[@B28]\]   Caucasian   54.4    37.1    8.4    ---

  5   Zeng et al. 2012 \[[@B29]\]       China       55.1    40.5    4.4    370
  --------------------------------------------------------------------------------

[^1]: Academic Editor: Xinhua Shu
